TOTAL FDCAs  perioda  
  N=2718 (%) Pre FDCAsa N= 1,654 (60.8%) Post FDCAsa N= 1,064 (39,2%) P valueb
Age (years) 40.4 (36.5-45.0)c 39.8 (36.5-44.4)c 41.2 (36.7-45.8)c <0.001
Age category ≤35 years
35-55 years
≥55 years		 605 (22.3)
1,947 (71.6)
166 (6.1)		 375 (22.7)
1,184 (71.6)
95 (5.7)		 230 (21.6)
763 (71.7)
71 (6.7)		 ns
Gender Men
Women		 1,981 (72.9)
737(27.1)		 1,227 (74.2)
427 (25.8)		 754 (70.9)
366 (29.1)		 0.06
Transmission group IDUd
Heterosexual
Men have sex with men 		1,058 (38.9)
772 (28.4)
542 (19.9)		 668 (40.4)
465 (28.1)
339 (20.5)		 390 (36.6)e:0.06
307 (28.9)e:ns
203 (19.1)e:ns 		ns
Country of origin Spain Others 2,568 (94.5)
150 (5.5)		 1,572 (95.0)
82 (4.8)		 996 (93.6)
68 (6.4)		 0.1
AIDS 990 (36.4) 615 (37.2) 375 (35.2) ns
CD4 (cells/μl) 298 (162-471)c 300 (166-470)c 290 (155.473.2)c ns
log10 HIV-1 RNA (copies/ml) 4.2 (3.6-4.8)c 4.1 (3.6-4.8)c 4.3 (3.6-4.8)c ns
Years since HIV+ diagnosis 10.8(6.8-14.4)c 10.5(6.6-13.9)c 11.4(7.2-5.6)c 0.0001
Class Drug Exposure:
One-class ARVs
Two-classARVs
Three- class ARVs		 138 (5.1)
1,093 (40.3)
1,484 (54.7)		 74 (4.5)
585 (35.4)
995 (60.2)		 64 (6.0)e:ns
508 (47.9)e<0.0001
489 (46.1)e<0.0001 		<0.0001
Number of treatment failures One failure
Two failures
Three or more failures 		536 (19.7)
616 (22.7)
1,566 (57.6)		 284 (17.2)
391 (23.6)
979 (59.2)		 252 (23.7)e<0.0001
225 (21.2)e:ns
587 (55.2)e:0.04 		<0.0001
Type of genotypic test Trugene Visible Genetics
Applied Biosystems Viroseq		 1,157 (42.7)
1,552 (57.3)		 760 (45.2)
886(53.8)		 397  (37.3)
666 (62.6)		 <0.0001
Drug- Class Resistance Any-class drug resistance
Two- class drug resistance
Multiple-classf drug resistance 		2,068 (76.1)
1,545 (56.8)
455 (16.7)		 1,390 (84.0)
1,075 (65.0)
354 (21.4)		 678 (63.7)
470 (44.2)
101 (9.5)		 <0.0001
<0.0001
<0.0001
GRg  to ARVs:
NRTIs
NNRTIs
PIs		 1,853 (68.2)
1,365 (50.2)
850 (31.3)		 1,274 (77.0)
930 (56.2)
615 (22.1)		 579  (54.4)
435 (40.9)
235  (16.1)		 <0.0001
<0.0001
<0.0001
aFDCAs period: Pre FDCAs: patients with genotypical resistance test made from January 2002 to June 2005; Post FDCAs patients with genotypical resistance test made from July 2005 to June 2008
bp value from chi-square test for qualitative variables, or Mann-Whitney U test for quantitative variables
cMedian and Interquartil range (IQR)
dIntravenous drug users
eP value from Z-test for proportions- Independent groups; ns: no significant
fConsidered as three-class drugs resistance
gGenotipical Resistances
Table 1: Differences in characteristic and genotypic resistances (GR) data among infected HIV population with treatment failure in Catalonia by FDCAs period.
Goto home»